Thursday, July 3, 2025 7/3/2025

Comparative modeling of sarcoma microenvironments for the discovery of biomarkers and tumor vulnerabilities

Award Number: R01CA258265
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 03/26/2021
PERIOD OF PERFORMANCE END DATE: 08/31/2026

Group Awards By:

View Award Description

Comparative modeling of sarcoma microenvironments for the discovery of biomarkers and tumor vulnerabilities - ABSTRACT Soft-tissue sarcomas are heterogeneous tumors that originate from cells belonging to the mesenchymal lineages, and that affect almost 200,000 individuals worldwide each year. The most aggressive and metastatic sub-types in adults are those with complex karyotypes and multiple genetic aberrations. The overall survival of these sarcoma patients has not greatly improved in recent years, and alternative approaches to chemotherapy and radiotherapy such as immunotherapy have so far provided only marginal benefits. Novel therapeutic advances for UPS are hindered by the lack of knowledge about the functional consequences of the complex genomic alterations found in patients and limited characterizations of the tumor microenvironment (TME), which would reveal non-cell-autonomous mechanisms critical to sarcoma progression. Experimental tools and available animal models currently do not address these limitations. However, appropriate models could facilitate the efficient discovery of new targets and immune- based therapies for these tumors, which have relatively low incidence and for which the development of clinical trials is often challenging. Accordingly, we propose to generate sarcoma mouse models that encompass the actual somatic aberrations observed in patients. Moreover, we will use these models to facilitate studies of treatment response and TME composition. The employment of these new models, together with newer technologies such as single-cell RNA- sequencing (scRNA-seq), CyTOF and Imaging Mass Cytometry (IMC) will ultimately illuminate the key expression profile of the single tumor cells, mechanisms of metastasis, resistance to conventional treatments and TME components that may influence such mechanisms. Ultimately, these models will translate to the clinic more effective therapeutic combinations and regimens. Successful completion of this project will i) generate new mouse models of complex sarcoma that recapitulate the genetic defects found in human sarcoma and provide a comprehensive functional characterization of these models (Aim 1), ii) illuminate the expression profile of the tumor cells and discrete sub-groups of them, to understand how these profiles influence the TME composition (Aim 2), iii) test how these models respond to different radiotherapy administration schedules in the heterogeneous settings of distinct tumor genetics, expression profiles and environmental elements (Aim 3).


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2024	CEDARS-SINAI MEDICAL CENTER	8700 BEVERLY BLVD	WEST HOLLYWOOD	CA	90048	LOS ANGELES	USA	Cancer Biology Research	000	4	4/17/2025	NON-COMPETING CONTINUATION	-$413,506
2025	2024	THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER	1515 HOLCOMBE BLVD	HOUSTON	TX	77030	HARRIS	USA	Cancer Biology Research	001	5	4/17/2025	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$413,506
2025	2024	THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER	1515 HOLCOMBE BLVD	HOUSTON	TX	77030	HARRIS	USA	Cancer Biology Research	003	5	6/17/2025	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$2,094
2025	2024	CEDARS-SINAI MEDICAL CENTER	8700 BEVERLY BLVD	WEST HOLLYWOOD	CA	90048	LOS ANGELES	USA	Cancer Biology Research	002	4	6/17/2025	NON-COMPETING CONTINUATION	-$2,094
														Subtotal = $0

Issue Date FY: 2024 ( Subtotal = $458,776 )
2024	2024	CEDARS-SINAI MEDICAL CENTER	8700 BEVERLY BLVD	WEST HOLLYWOOD	CA	90048	LOS ANGELES	USA	Cancer Biology Research	001	4	4/17/2024	NON-COMPETING CONTINUATION	$24,147
2024	2024	CEDARS-SINAI MEDICAL CENTER	8700 BEVERLY BLVD	WEST HOLLYWOOD	CA	90048	LOS ANGELES	USA	Cancer Biology Research	000	4	2/7/2024	NON-COMPETING CONTINUATION	$434,629
														Subtotal = $458,776

Issue Date FY: 2023 ( Subtotal = $473,262 )
2023	2023	CEDARS-SINAI MEDICAL CENTER	8700 BEVERLY BLVD	WEST HOLLYWOOD	CA	90048	LOS ANGELES	USA	Cancer Biology Research	000	3	2/23/2023	NON-COMPETING CONTINUATION	$473,262
														Subtotal = $473,262

Issue Date FY: 2022 ( Subtotal = $482,921 )
2022	2022	CEDARS-SINAI MEDICAL CENTER	8700 BEVERLY BLVD	LOS ANGELES	CA	90048	LOS ANGELES	USA	Cancer Biology Research	000	2	2/23/2022	NON-COMPETING CONTINUATION	$434,626
2022	2022	CEDARS-SINAI MEDICAL CENTER	8700 BEVERLY BLVD	LOS ANGELES	CA	90048	LOS ANGELES	USA	Cancer Biology Research	001	2	5/25/2022	NON-COMPETING CONTINUATION	$48,295
														Subtotal = $482,921

Issue Date FY: 2021 ( Subtotal = $443,656 )
2021	2021	CEDARS-SINAI MEDICAL CENTER	8700 BEVERLY BLVD	LOS ANGELES	CA	90048	LOS ANGELES	USA	Cancer Biology Research	000	1	3/26/2021	NEW	$443,656
														Subtotal = $443,656

Grand Total All Awards = $1,858,615

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Comparative modeling of sarcoma microenvironments for the discovery of biomarkers and tumor vulnerabilities

Award Number: R01CA258265

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 03/26/2021

PERIOD OF PERFORMANCE END DATE: 08/31/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer